Cisplatin binding to proteins: A structural perspective

Messori, Luigi; Merlino, Antonello

doi:10.1016/j.ccr.2016.01.010

Cited by 139 publications

(119 citation statements)

References 169 publications

Supporting

Mentioning

108

Contrasting

Unclassified

Order By: Relevance

“…L 24 and C 24 were evaluated against bacteria B. subtilis (G + ) and P. aeruginosa (G À ). Remarkable antimicrobial activities were recorded for L 24 and C 24 against test microbes with an MIC value of 15.6 mg/mL for each (Table 1). Again, the substitution of more bulky group in a thiosemicarbazone ligand at N(4) position enhanced the biological activity.…”

Section: Mn-complexes With Tridentate Ligandsmentioning

confidence: 99%

Coordination Complexes of Manganese and Their Biomedical Applications

Ali

Iqbal

2017

ChemistrySelect

View full text Add to dashboard Cite

The clinical success of metallodrugs is rapidly increasing. The historical use of cisplatin and recently a successful marketing of its clinically advanced derivatives (oxaliplatin, carboplatin, nedaplatin, lobaplatin and heptaplatin) for the treatment of various types of cancer has opened new horizons for metal based drugs. Complexes of cobalt, gold, ruthenium, palladium, manganese and even arsenic are either being marketed or close to get success in clinical trials for the treatment of various diseases. Current review compiles the advances on manganese complexes and their biomedical applications. A possible structure activity relationship has been discussed.

show abstract

Section: Mn-complexes With Tridentate Ligandsmentioning

confidence: 99%

Coordination Complexes of Manganese and Their Biomedical Applications

Ali

Iqbal

2017

ChemistrySelect

View full text Add to dashboard Cite

show abstract

“…Nearly five decades after the discovery of the anti‐cancer activity of cisplatin, platinum‐based compounds are still used in more than 50 % of all chemotherapeutic applications The interest in platinum‐based anti‐cancer agents has grown exponentially, with improvements being made to the pharmacokinetic and pharmacodynamic aspects of the drugs to yield a small but potent library of platinum‐containing anti‐cancer agents (Figure ) , . Some of these compounds are poorly soluble in aqueous environments and plagued by several side‐effects, ranging from bone marrow suppression to acute nephrotoxicity and, ultimately, the emergence of intrinsic and extrinsic platinum resistant cancers …”

Section: Introductionmentioning

confidence: 99%

“…A summary of the most successful metal‐containing anti‐cancer agents. A) The platinum‐based anti‐cancer agents clinically applied today, B) alternative mononuclear anti‐cancer agents …”

Section: Introductionmentioning

confidence: 99%

Heterometallic Multinuclear Complexes as Anti‐Cancer Agents‐An Overview of Recent Developments

2019

View full text Add to dashboard Cite

This review provides a critical assessment of the advances made in the development of heterometallic multinuclear complexes as potential chemotherapeutic agents, with the aim of providing a starting point for future investigators. The combination of the classical transition metals (Pt, Ru and Au) with other metal moieties has the potential to result in complexes with improved pharmacokinetic and pharmacodynamic properties. This enables selective targeting of the bio- [a] 3434 Figure 2. The Pt II -Ru III complexes, IT127 and AH-197, [35] and the macrocyclic rectangles investigated by Chi and colleagues. [36] The IC 50 (μM) values reported are shown below the chemical structures.

show abstract

“…[2] Recently,t here has been increasing awareness that some tumor-associated proteins may be binding partners of Ptbased anticancer complexes. [4] Ligands make crucial contributions to the binding and reaction kinetics of anticancer metal complexes under cellular conditions. [4] Ligands make crucial contributions to the binding and reaction kinetics of anticancer metal complexes under cellular conditions.…”

mentioning

confidence: 99%

An Antitumor Bis(N‐Heterocyclic Carbene)Platinum(II) Complex That Engages Asparagine Synthetase as an Anticancer Target

Hu,

Yang,

Lok

et al. 2019

Angew Chem Int Ed

View full text Add to dashboard Cite

New anticancer platinum(II) compounds with distinctive modes of action are appealing alternatives to combat the drug resistance and improve the efficacy of clinically used platinum chemotherapy. Herein, we describe arare example of an antitumor Pt II complex targeting at umor-associated protein, rather than DNA, under cellular conditions.Complex [(bis-NHC)Pt(bt)]PF 6 (1a;H bt = 1-(3-hydroxybenzo-[b]thiophen-2-yl)ethanone) overcomes cisplatin resistance in cancer cells and displays significant tumor growth inhibition in mice with higher tolerable doses compared to cisplatin. The cellular Pt species shows little association with DNA, and localizes in the cytoplasm as revealed by nanoscale secondary ion mass spectrometry.Anunbiased thermal proteome profiling experiment identified asparagine synthetase (ASNS) as am olecular target of 1a.A ccordingly, 1a treatment reduced the cellular asparagine levels and inhibited cancer cell proliferation, which could be reversed by asparagine supplementation. Ab is-NHC-ligated Pt species generated from the hydrolysis of 1a forms adducts with thiols and appears to target an active-site cysteine of ASNS.

show abstract

Cisplatin binding to proteins: A structural perspective

Cited by 139 publications

References 169 publications

Coordination Complexes of Manganese and Their Biomedical Applications

Coordination Complexes of Manganese and Their Biomedical Applications

Heterometallic Multinuclear Complexes as Anti‐Cancer Agents‐An Overview of Recent Developments

An Antitumor Bis(N‐Heterocyclic Carbene)Platinum(II) Complex That Engages Asparagine Synthetase as an Anticancer Target

Contact Info

Product

Resources

About